Literature DB >> 29716728

p63 Silencing induces reprogramming of cardiac fibroblasts into cardiomyocyte-like cells.

Vivekkumar Patel1, Vivek P Singh1, Jaya Pratap Pinnamaneni1, Deepthi Sanagasetti1, Jacqueline Olive1, Megumi Mathison1, Austin Cooney2, Elsa R Flores3, Ronald G Crystal4, Jianchang Yang1, Todd K Rosengart5.   

Abstract

OBJECTIVE: Reprogramming of fibroblasts into induced cardiomyocytes represents a potential new therapy for heart failure. We hypothesized that inactivation of p63, a p53 gene family member, may help overcome human cell resistance to reprogramming.
METHODS: p63 Knockout (-/-) and knockdown murine embryonic fibroblasts (MEFs), p63-/- adult murine cardiac fibroblasts, and human cardiac fibroblasts were assessed for cardiomyocyte-specific feature changes, with or without treatment by the cardiac transcription factors Hand2-Myocardin (HM).
RESULTS: Flow cytometry revealed that a significantly greater number of p63-/- MEFs expressed the cardiac-specific marker cardiac troponin T (cTnT) in culture compared with wild-type (WT) cells (38% ± 11% vs 0.9% ± 0.9%, P < .05). HM treatment of p63-/- MEFs increased cTnT expression to 74% ± 3% of cells but did not induce cTnT expression in wild-type murine embryonic fibroblasts. shRNA-mediated p63 knockdown likewise yielded a 20-fold increase in cTnT microRNA expression compared with untreated MEFs. Adult murine cardiac fibroblasts demonstrated a 200-fold increase in cTnT gene expression after inducible p63 knockout and expressed sarcomeric α-actinin as well as cTnT. These p63-/- adult cardiac fibroblasts exhibited calcium transients and electrically stimulated contractions when co-cultured with neonatal rat cardiomyocytes and treated with HM. Increased expression of cTnT and other marker genes was also observed in p63 knockdown human cardiac fibroblasts procured from patients undergoing procedures for heart failure.
CONCLUSIONS: Downregulation of p63 facilitates direct cardiac cellular reprogramming and may help overcome the resistance of human cells to reprogramming.
Copyright © 2018 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cellular reprogramming; heart failure; induced-cardiomyocytes (iCMs); myocardial infarction; regenerative medicine; transdifferentiation

Mesh:

Substances:

Year:  2018        PMID: 29716728      PMCID: PMC6050095          DOI: 10.1016/j.jtcvs.2018.03.162

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  35 in total

1.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Clyde W Yancy; Mariell Jessup; Biykem Bozkurt; Javed Butler; Donald E Casey; Mark H Drazner; Gregg C Fonarow; Stephen A Geraci; Tamara Horwich; James L Januzzi; Maryl R Johnson; Edward K Kasper; Wayne C Levy; Frederick A Masoudi; Patrick E McBride; John J V McMurray; Judith E Mitchell; Pamela N Peterson; Barbara Riegel; Flora Sam; Lynne W Stevenson; W H Wilson Tang; Emily J Tsai; Bruce L Wilkoff
Journal:  Circulation       Date:  2013-06-05       Impact factor: 29.690

2.  "Triplet" polycistronic vectors encoding Gata4, Mef2c, and Tbx5 enhances postinfarct ventricular functional improvement compared with singlet vectors.

Authors:  Megumi Mathison; Vivek P Singh; Robert P Gersch; Maricela O Ramirez; Austin Cooney; Stephen M Kaminsky; Maria J Chiuchiolo; Ahmed Nasser; Jianchang Yang; Ronald G Crystal; Todd K Rosengart
Journal:  J Thorac Cardiovasc Surg       Date:  2014-03-27       Impact factor: 5.209

3.  Reprogramming of human fibroblasts toward a cardiac fate.

Authors:  Young-Jae Nam; Kunhua Song; Xiang Luo; Edward Daniel; Kaleb Lambeth; Katherine West; Joseph A Hill; J Michael DiMaio; Linda A Baker; Rhonda Bassel-Duby; Eric N Olson
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-04       Impact factor: 11.205

4.  Suppression of induced pluripotent stem cell generation by the p53-p21 pathway.

Authors:  Hyenjong Hong; Kazutoshi Takahashi; Tomoko Ichisaka; Takashi Aoi; Osami Kanagawa; Masato Nakagawa; Keisuke Okita; Shinya Yamanaka
Journal:  Nature       Date:  2009-08-09       Impact factor: 49.962

Review 5.  The roles of p63 in cancer.

Authors:  Elsa R Flores
Journal:  Cell Cycle       Date:  2007-02-03       Impact factor: 4.534

6.  Induction of human cardiomyocyte-like cells from fibroblasts by defined factors.

Authors:  Rie Wada; Naoto Muraoka; Kohei Inagawa; Hiroyuki Yamakawa; Kazutaka Miyamoto; Taketaro Sadahiro; Tomohiko Umei; Ruri Kaneda; Tomoyuki Suzuki; Kaichiro Kamiya; Shugo Tohyama; Shinsuke Yuasa; Kiyokazu Kokaji; Ryo Aeba; Ryohei Yozu; Hiroyuki Yamagishi; Toshio Kitamura; Keiichi Fukuda; Masaki Ieda
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-16       Impact factor: 11.205

7.  TAp63 induces senescence and suppresses tumorigenesis in vivo.

Authors:  Xuecui Guo; William M Keyes; Cristian Papazoglu; Johannes Zuber; Wangzhi Li; Scott W Lowe; Hannes Vogel; Alea A Mills
Journal:  Nat Cell Biol       Date:  2009-11-08       Impact factor: 28.824

8.  p53 regulates a mitotic transcription program and determines ploidy in normal mouse liver.

Authors:  Svitlana Kurinna; Sabrina A Stratton; Zeynep Coban; Jill M Schumacher; Markus Grompe; Andrew W Duncan; Michelle Craig Barton
Journal:  Hepatology       Date:  2013-02-15       Impact factor: 17.425

9.  Tumor Protein p63/microRNA Network in Epithelial Cancer Cells.

Authors:  Edward A Ratovitski
Journal:  Curr Genomics       Date:  2013-11       Impact factor: 2.236

10.  Transient p53 suppression increases reprogramming of human fibroblasts without affecting apoptosis and DNA damage.

Authors:  Mikkel A Rasmussen; Bjørn Holst; Zeynep Tümer; Mads G Johnsen; Shuling Zhou; Tina C Stummann; Poul Hyttel; Christian Clausen
Journal:  Stem Cell Reports       Date:  2014-08-21       Impact factor: 7.765

View more
  7 in total

1.  Silencing or not silencing p63 in cardiac fibroblast, risks and benefits.

Authors:  Guillermo Díaz-Araya; Jenaro Antonio Espitia-Corredor
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

2.  Commentary: Alas, we are not yet zebrafish.

Authors:  Christopher T Ryan; Todd K Rosengart
Journal:  J Thorac Cardiovasc Surg       Date:  2020-01-07       Impact factor: 5.209

3.  p63 silencing induces epigenetic modulation to enhance human cardiac fibroblast to cardiomyocyte-like differentiation.

Authors:  Jaya Pratap Pinnamaneni; Vivek P Singh; Mary B Kim; Christopher T Ryan; Aarthi Pugazenthi; Deepthi Sanagasetti; Megumi Mathison; Jianchang Yang; Todd K Rosengart
Journal:  Sci Rep       Date:  2022-07-06       Impact factor: 4.996

4.  Hippo Pathway Effector Tead1 Induces Cardiac Fibroblast to Cardiomyocyte Reprogramming.

Authors:  Vivek P Singh; Jaya P Pinnamaneni; Aarthi Pugazenthi; Deepthi Sanagasetti; Megumi Mathison; James F Martin; Jianchang Yang; Todd K Rosengart
Journal:  J Am Heart Assoc       Date:  2021-12-10       Impact factor: 6.106

5.  Enhanced Generation of Induced Cardiomyocytes Using a Small-Molecule Cocktail to Overcome Barriers to Cardiac Cellular Reprogramming.

Authors:  Vivek P Singh; Jaya Pratap Pinnamaneni; Aarthi Pugazenthi; Deepthi Sanagasetti; Megumi Mathison; Kai Wang; Jianchang Yang; Todd K Rosengart
Journal:  J Am Heart Assoc       Date:  2020-06-05       Impact factor: 5.501

6.  Clinical potential of angiogenic therapy and cellular reprogramming.

Authors:  Christopher T Ryan; Vivek Patel; Todd K Rosengart
Journal:  JTCVS Open       Date:  2021-03-18

7.  Fibroblast transition to an endothelial "trans" state improves cell reprogramming efficiency.

Authors:  Megumi Mathison; Deepthi Sanagasetti; Vivek P Singh; Aarthi Pugazenthi; Jaya Pratap Pinnamaneni; Christopher T Ryan; Jianchang Yang; Todd K Rosengart
Journal:  Sci Rep       Date:  2021-11-19       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.